Compare PRK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | IRON |
|---|---|---|
| Founded | 1908 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.1B |
| IPO Year | 1996 | 2020 |
| Metric | PRK | IRON |
|---|---|---|
| Price | $179.11 | $65.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $184.00 | $103.18 |
| AVG Volume (30 Days) | 86.0K | ★ 473.9K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $664,421,000.00 | N/A |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $3.63 | $283.52 |
| P/E Ratio | $32.18 | ★ N/A |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $149.06 | $40.00 |
| 52 Week High | $215.00 | $99.50 |
| Indicator | PRK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 28.72 |
| Support Level | $170.74 | $65.04 |
| Resistance Level | $182.34 | $72.68 |
| Average True Range (ATR) | 3.68 | 2.89 |
| MACD | -0.30 | -0.50 |
| Stochastic Oscillator | 3.79 | 13.38 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.